Pemvidutide: GLP-1/glucagon dual agonist for obesity and MASH. Pivotal MASH IMPACT data expected 2026. MASH-first positioning differentiates from obesity-focused peers.
Pemvidutide: GLP-1/glucagon dual agonist for obesity and MASH. Pivotal MASH IMPACT data expected 2026. MASH-first positioning differentiates from obesity-focused peers.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling: